Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:44:34 EDT Tue 02 Sep 2025
Enter Symbol
or Name
USA
CA



Q:SGMO - SANGAMO THERAPEUTICS INC - https://www.sangamo.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SGMO - Q0.30.531·0.7010.00.5394+0.01943.73,691.61,8363,4170.53  0.55  0.52233.175  0.41219:57:44Aug 0715 min RT 2¢

Recent Trades - Last 10 of 3417
Time ETExPriceChangeVolume
19:57:44Q0.540.0232
19:56:46Q0.53990.0199920
19:55:39Q0.540.026,500
19:55:39Q0.54010.02013,498
19:55:39Q0.54010.0201400
19:55:05Q0.54010.0201100
19:51:02Q0.5450.02590
19:28:45Q0.5450.02584
19:28:29Q0.5450.025200
19:28:15Q0.5450.0251

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-08-07 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
2025-07-31 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Second Quarter 2025 Earnings Call
2025-06-24 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
2025-05-12 18:26U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
2025-05-12 18:23U:SGMONews ReleaseSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
2025-05-12 16:00U:SGMONews ReleaseSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
2025-05-06 16:35U:SGMONews ReleaseSangamo Therapeutics Announces First Quarter 2025 Earnings Call
2025-05-06 08:30U:SGMONews ReleaseSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
2025-04-28 16:31U:SGMONews ReleaseSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2025-04-03 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
2025-03-17 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
2025-03-06 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
2025-02-06 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
2024-12-30 16:15U:SGMONews ReleaseSangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec
2024-12-19 02:30U:SGMONews ReleaseSangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
2024-12-19 02:30U:SGMONews ReleaseAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
2024-11-19 16:15U:SGMONews ReleaseSangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
2024-11-12 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
2024-11-04 16:15U:SGMONews ReleaseSangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
2024-10-22 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025